Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn’s disease patients

Anti-tumor necrosis factor (TNF) therapy is used to induce and maintain remission in Crohn’s disease (CD) patients. However, primary non-responders to initial treatment constitute 20–40% of cases. The causes of this phenomenon are still unknown. We aim to investigate the impact of the caspase 9 (CAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lykowska-Szuber, Liliana, Walczak, Michal, Stawczyk-Eder, Kamila, Krela-Kazmierczak, Iwona, Eder, Piotr, Zakerska-Banaszak, Oliwia, Dobrowolska, Agnieszka, Skrzypczak-Zielinska, Marzena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Human Genetics • Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632275/
https://www.ncbi.nlm.nih.gov/pubmed/37658984
http://dx.doi.org/10.1007/s13353-023-00783-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632275/
https://www.ncbi.nlm.nih.gov/pubmed/37658984
http://dx.doi.org/10.1007/s13353-023-00783-7

Ejemplares similares